Newer developments in the immunotherapy of malignant melanoma
| Autor: | Constantin A Dasanu, Thomas E. Ichim, Doru T. Alexandrescu, Benjamin Maslin |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.drug_class
medicine.medical_treatment Antigen presentation Ipilimumab Monoclonal antibody Immune system Medicine Animals Humans Pharmacology (medical) CTLA-4 Antigen Melanoma biology business.industry Antibodies Monoclonal Immunotherapy medicine.disease Cytokine Oncology Immunology biology.protein Antibody business medicine.drug |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 20(1) |
| ISSN: | 1477-092X |
| Popis: | Individuals with malignant melanoma present a variety of immune abnormalities including but not limited to cellular immune dysfunction, antigen presentation deficits, and cytokine production defects. Therefore, enhancing the immune system potential represents an appealing avenue for melanoma therapy. The authors review the immune therapies currently in clinical use as well as the most promising immunotherapy candidates. Ipilimumab, a monoclonal antibody against the CTLA-4, was approved for the therapy of advanced melanoma in 2011. In addition, sizeable anti-melanoma activity has recently been shown with the use of other agents including anti-PD-1/anti-PD-1 ligand antibodies. Consequently, these experimental immunotherapy agents may soon become important items in the anti-melanoma armamentarium. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|